Corcept Therapeutics (CORT) officer reports stock awards and tax withholding move

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics officer Joseph Douglas Lyon reported routine equity compensation activity in the company’s common stock. On March 2, 2026, he acquired 398 shares in a grant or award and another 398 shares tied to a purchase plan, with the price based on that day’s closing price.

On March 3, 2026, 89 shares were disposed of through share withholding to cover tax obligations related to vesting restricted stock units, rather than an open-market sale. Following these transactions, he directly holds 11,230 shares, including unvested restricted stock awards that generally vest one year after their grant dates if required conditions are met.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Lyon Joseph Douglas

Role See Remarks

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	89	$35.97	$3K
Grant/Award	Common Stock	398	$35.97	$14K
Grant/Award	Common Stock	398	$0.00	--

Holdings After Transaction: Common Stock — 11,230 shares (Direct)

Footnotes (1)

The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Includes 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. The closing price on March 2, 2026 was used to calculate the withholding obligation. Includes 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 . 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Form 4 Insider Transactions: What Each Field Means →

03/04/2026 - 08:26 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lyon Joseph Douglas

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

94065

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		A		398⁽¹⁾	A	$35.97⁽²⁾	10,921⁽³⁾	D
Common Stock	03/02/2026		A		398⁽⁴⁾	A	$0.00	11,319⁽³⁾	D
Common Stock	03/03/2026		F⁽⁵⁾		89	D	$35.97⁽⁶⁾	11,230⁽⁷⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

6. The closing price on March 2, 2026 was used to calculate the withholding obligation.

7. Includes 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 . 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Remarks:

Chief Accounting & Technology Officer

	/s/ Joseph Douglas Lyon	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Corcept Therapeutics (CORT) report for Joseph Douglas Lyon?

Corcept Therapeutics reported that officer Joseph Douglas Lyon received two equity awards totaling 796 common shares and had 89 shares withheld for taxes. These were routine compensation and tax-withholding transactions, not open-market purchases or sales.

Did the Corcept Therapeutics (CORT) insider sell shares on the open market?

No open-market sale was reported. The 89-share disposition on March 3, 2026 was a tax-withholding transaction, where shares were withheld by the company to satisfy tax obligations connected to vesting restricted stock units.

How many Corcept Therapeutics (CORT) shares does Joseph Douglas Lyon hold after these transactions?

After these transactions, Joseph Douglas Lyon directly holds 11,230 shares of Corcept Therapeutics common stock. This total includes shares underlying unvested restricted stock awards that will vest after one year if specified service and ownership conditions are satisfied.

What equity awards did the Corcept Therapeutics (CORT) officer receive on March 2, 2026?

On March 2, 2026, the officer received two non-derivative common stock awards of 398 shares each. One block relates to a purchase plan under the 2024 Incentive Award Plan, and the price was based on the closing share price that day.

How do Corcept Therapeutics (CORT) restricted stock awards for this insider vest?

Restricted stock awards for this insider generally vest 100% on the one-year anniversary of the grant date. Vesting requires that he satisfy specified requirements, including continued service and, for certain awards, remaining the beneficial owner of the purchase plan shares.